Equities

Fusion Antibodies PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
FAB:LSE

Fusion Antibodies PLC

Actions
Health CareHealth Care Providers
  • Price (GBX)15.11
  • Today's Change-0.64 / -4.06%
  • Shares traded434.38k
  • 1 Year change+108.41%
  • Beta2.1699
Data delayed at least 20 minutes, as of Feb 10 2026 14:41 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The Company offers an integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development. It offers a range of services including antibody discovery/generation, development, characterization, optimization, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanization using Fusion's proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for downstream use by the customer to produce material for clinical trials. Its Integrated Therapeutic Antibody Services (ITA) offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.

  • Revenue in GBP (TTM)1.60m
  • Net income in GBP-1.47m
  • Incorporated2000
  • Employees24.00
  • Location
    Fusion Antibodies PLCSpringbank Industrial Estate1 Springbank RoadBELFAST BT17 0QLUnited KingdomGBR
  • Phone+44 289 043 2800
  • Fax+44 289 002 0446
  • Websitehttps://fusionantibodies.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
N4 Pharma PLC7.07k-1.07m3.95m4.00--2.24--559.17-0.0025-0.00250.000020.00210.0045--0.07561,767.50-71.04-59.59-74.91-63.90-----15,981.33-67,987.22----0.00--273.33--16.60------
TheraCryf PLC0.00-2.01m4.51m9.00--0.9398-----0.0017-0.00170.000.00220.00----0.00-41.20-38.70-53.79-42.97-------1,407.46----0.00---100.00--38.13------
Cizzle Biotechnology Holdings PLC0.00-1.12m6.14m67.00---------0.0028-0.00280.00-0.00070.00-------190.34-146.14-433.59-169.40--------0.4766-2.42---------26.15------
Talisman Metals PLC0.0065.26k6.75m1.00--2.82103.48---0.0064-0.0160.000.03730.00----0.003.15-30.403.64-33.15------------0.00------99.94------
OptiBiotix Health PLC1.15m-191.00k7.90m5.00--0.9385564.466.87-0.0018-0.00180.01130.08150.1341.932.88230,200.00-2.2217.23-2.3317.8445.4450.78-16.59189.343.75--0.0094.9335.093.1511.48------
Futura Medical PLC7.93m-6.29m8.14m12.00--1.40--1.03-0.0207-0.02070.02610.011.06137.368.58---84.19-45.00-112.42-71.7970.67---79.41-108.252.21--0.00--349.09237.55119.85--121.02--
IXICO PLC6.53m-1.65m9.50m79.00--0.8093--1.45-0.0186-0.01860.0730.12670.5222--3.1882,708.86-13.19-3.47-15.43-4.0348.7155.52-25.27-6.21----0.015--13.32-7.2717.49---5.30--
Genflow Biosciences PLC0.00-1.80m10.36m5.00---------0.005-0.0050.00-0.00070.00----0.00-197.92---648.46----------------------14.68------
Solvonis Therapeutics PLC0.00-2.60m17.70m----2.22-----0.001-0.0010.000.00120.00-------44.49---54.32-------------645.250.011---100.00--53.62------
Fusion Antibodies PLC1.60m-1.47m19.69m24.00--24.66--12.34-0.0144-0.01440.01520.00640.95574.961.9666,500.00-87.84-56.24-137.88-73.6722.0636.41-91.92-71.051.45-190.630.3483--72.98-12.7923.05---37.98--
Sareum Holdings Plc0.00-4.44m23.47m5.00--10.04-----0.0365-0.03650.000.01690.00----0.00-126.85-93.37-202.14-118.41------------0.00-------29.77------
Arecor Therapeutics PLC5.06m-8.10m29.26m37.00--10.25--5.78-0.2208-0.22080.13680.07560.648218.581.93136,783.80-103.79-53.69-187.88-68.26-2.45---160.13-248.392.00--0.0571--10.50---19.66------
Data as of Feb 10 2026. Currency figures normalised to Fusion Antibodies PLC's reporting currency: UK Pound GBX

Institutional shareholders

24.03%Per cent of shares held by top holders
HolderShares% Held
Rathbones Investment Management Ltd.as of 04 Feb 20269.68m8.52%
Unicorn Asset Management Ltd.as of 30 Jan 20268.32m7.32%
Canaccord Genuity Wealth Ltd.as of 30 Sep 20257.83m6.89%
Octopus Investments Ltd.as of 31 Aug 20251.46m1.29%
Oberon Investments Ltd. (GB Investment Management)as of 30 Jun 20258.31k0.01%
More ▼
Data from 31 Oct 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.